These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 30259646)

  • 1. Unrelated allogeneic hematopoietic stem cell transplantation in a patient with Revesz syndrome, a severe variant of dyskeratosis congenita.
    Watanabe K; Arakawa Y; Kambe T; Oguma E; Kishimoto H; Koh K
    Pediatr Blood Cancer; 2019 Jan; 66(1):e27476. PubMed ID: 30259646
    [No Abstract]   [Full Text] [Related]  

  • 2. Allogeneic hematopoietic stem cell transplantation for dyskeratosis congenita.
    Elmahadi S; Muramatsu H; Kojima S
    Curr Opin Hematol; 2016 Nov; 23(6):501-507. PubMed ID: 27607446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel mutation of the TINF2 gene resulting in severe phenotypic Revesz syndrome.
    Sakwit A; Rojanaporn D; Mekjaruskul P; Suriyajakryuththana W; Sasanakul W; Sirachainan N
    Pediatr Blood Cancer; 2019 Mar; 66(3):e27557. PubMed ID: 30478948
    [No Abstract]   [Full Text] [Related]  

  • 4. Bilateral Exudative Retinopathy in a Child with Revesz Syndrome, a Severe Variant of Dyskeratosis Congenita.
    Adams C; Say E; Cheeseman EW
    Ophthalmol Retina; 2021 Nov; 5(11):1106. PubMed ID: 34752304
    [No Abstract]   [Full Text] [Related]  

  • 5. Reduced intensity conditioning regimen with fludarabine, cyclophosphamide, low dose TBI and alemtuzumab leading to successful unrelated umbilical cord stem cell engraftment and survival in two children with dyskeratosis congenita.
    Brown M; Myers D; Shreve N; Rahmetullah R; Radhi M
    Bone Marrow Transplant; 2016 May; 51(5):744-6. PubMed ID: 26808569
    [No Abstract]   [Full Text] [Related]  

  • 6. Hematopoietic cell transplantation in Fanconi anemia and dyskeratosis congenita: A minireview.
    Ayas M
    Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):285-289. PubMed ID: 28644950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for treatment of Dyskeratosis congenita.
    Güngör T; Corbacioglu S; Storb R; Seger RA
    Bone Marrow Transplant; 2003 Mar; 31(5):407-10. PubMed ID: 12634734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffuse hemorrhagic colitis in a patient with dyskeratosis congenita after nonmyeloablative allogeneic hematopoietic stem cell transplantation.
    Ehlert K; Rossig C; Groll AH; Beyna T; Froehlich B; Juergens H
    J Pediatr Hematol Oncol; 2015 Jan; 37(1):e41-4. PubMed ID: 25000468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced intensity conditioning is effective for hematopoietic SCT in dyskeratosis congenita-related BM failure.
    Ayas M; Nassar A; Hamidieh AA; Kharfan-Dabaja M; Othman TB; Elhaddad A; Seraihy A; Hussain F; Alimoghaddam K; Ladeb S; Fahmy O; Bazarbachi A; Mohamed SY; Bakr M; Korthof E; Aljurf M; Ghavamzadeh A
    Bone Marrow Transplant; 2013 Sep; 48(9):1168-72. PubMed ID: 23542225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita.
    Gadalla SM; Sales-Bonfim C; Carreras J; Alter BP; Antin JH; Ayas M; Bodhi P; Davis J; Davies SM; Deconinck E; Deeg HJ; Duerst RE; Fasth A; Ghavamzadeh A; Giri N; Goldman FD; Kolb EA; Krance R; Kurtzberg J; Leung WH; Srivastava A; Or R; Richman CM; Rosenberg PS; Toledo Codina JS; Shenoy S; Socié G; Tolar J; Williams KM; Eapen M; Savage SA
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1238-43. PubMed ID: 23751955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Reduced-Intensity Conditioning Regimen for Patients with Dyskeratosis Congenita Undergoing Hematopoietic Stem Cell Transplantation.
    Nelson AS; Marsh RA; Myers KC; Davies SM; Jodele S; O'Brien TA; Mehta PA
    Biol Blood Marrow Transplant; 2016 May; 22(5):884-8. PubMed ID: 26845033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita.
    Fioredda F; Iacobelli S; Korthof ET; Knol C; van Biezen A; Bresters D; Veys P; Yoshimi A; Fagioli F; Mats B; Zecca M; Faraci M; Miano M; Arcuri L; Maschan M; O'Brien T; Diaz MA; Sevilla J; Smith O; Peffault de Latour R; de la Fuente J; Or R; Van Lint MT; Tolar J; Aljurf M; Fisher A; Skorobogatova EV; Diaz de Heredia C; Risitano A; Dalle JH; Sedláček P; Ghavamzadeh A; Dufour C
    Br J Haematol; 2018 Oct; 183(1):110-118. PubMed ID: 29984823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic Hematopoietic Cell Transplantation for Dyskeratosis Congenita: A Report of 3 Cases.
    Tamura S; Imamura T; Urata T; Kobayashi M; Gen M; Tomii T; Do J; Osone S; Ishida H; Hosoi H; Kuroda H
    J Pediatr Hematol Oncol; 2017 Oct; 39(7):e394-e398. PubMed ID: 28538506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful T-cell-depleted haploidentical hematopoietic stem cell transplantation in a child with dyskeratosis congenita after a fludarabine-based conditioning regimen.
    Algeri M; Comoli P; Strocchio L; Perotti C; Corbella F; Del Fante C; Baio A; Giorgiani G; Gurrado A; Accornero E; Cugno C; Pession A; Zecca M
    J Pediatr Hematol Oncol; 2015 May; 37(4):322-6. PubMed ID: 25374286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic hematopoietic stem cell transplantation for inherited bone marrow failure syndromes.
    Dalle JH; Peffault de Latour R
    Int J Hematol; 2016 Apr; 103(4):373-9. PubMed ID: 26872907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular Findings of Revesz Syndrome in a 12-Year-Old Girl.
    Trivedi MG; Rai PJ; Shirwadkar SP; Pagad HS; Potdar NA; Shinde CA; Nair AG
    J Pediatr Ophthalmol Strabismus; 2016; 53(2):128. PubMed ID: 27018886
    [No Abstract]   [Full Text] [Related]  

  • 17. Fatal diffuse capillaritis after hematopoietic stem-cell transplantation for dyskeratosis congenita despite low-intensity conditioning regimen.
    Brazzola P; Duval M; Fournet JC; Gauvin F; Dalle JH; Champagne J; Champagne MA
    Bone Marrow Transplant; 2005 Dec; 36(12):1103-5; author reply 1105. PubMed ID: 16205731
    [No Abstract]   [Full Text] [Related]  

  • 18. A reduced intensity conditioning regimen of fludarabine, cyclophosphamide, antithymocyte globulin, plus 2 Gy TBI facilitates successful hematopoietic cell engraftment in an adult with dyskeratosis congenita.
    Kharfan-Dabaja MA; Otrock ZK; Bacigalupo A; Mahfouz RA; Geara F; Bazarbachi A
    Bone Marrow Transplant; 2012 Sep; 47(9):1254-5. PubMed ID: 22246089
    [No Abstract]   [Full Text] [Related]  

  • 19. Allogeneic stem cell transplantation in a patient with dyskeratosis congenita after conditioning with low-dose cyclophosphamide and anti-thymocyte globulin.
    Ayas M; Al-Musa A; Al-Jefri A; Al-Seraihi A; Al-Mahr M; Rifai S; El-Solh H
    Pediatr Blood Cancer; 2007 Jul; 49(1):103-4. PubMed ID: 16317729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced-intensity conditioning for alternative donor hematopoietic stem cell transplantation in patients with dyskeratosis congenita.
    Nishio N; Takahashi Y; Ohashi H; Doisaki S; Muramatsu H; Hama A; Shimada A; Yagasaki H; Kojima S
    Pediatr Transplant; 2011 Mar; 15(2):161-6. PubMed ID: 21176016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.